A beginner’s guide to Evosep

Nicolai Bache, Head of Applications at Evosep, will host the event, bringing you up to speed with the latest additions to the Evosep One technology.

At the end you will have the opportunity to ask questions to all the speakers.

Program:

1. CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target

Cellular thermal shift assay (CETSA) coupled with high-resolution mass-spectrometry (MS) is a powerful method to delineate direct and indirect interactions between small molecules and protein targets in intact cells. Biologically active compounds can induce changes in thermal stability, in their primary binding partners, and in proteins that in turn interact with the direct targets .This study aims to assess these host cell targets for a panel of FDA-approved antiviral compounds including remdesivir in noninfected cells.

Presenter: Alexey Chernobrovkin (Senior Research Scientist, Pelago Bioscience)

2. Assessing Parkinson’s Disease-linked LRRK2 kinase activity by multiplexed targeted mass spectrometry

Mutations that increase the protein kinase activity of LRRK2 are one of the most common causes of familial Parkinson’s disease. LRRK2 phosphorylates a subset of Rab GTPases within their Switch-II motif, impacting interaction with effectors. We describe and validate a new, multiplexed targeted mass spectrometry assay assisted with EvoSep One LC system to quantify endogenous levels of LRRK2-phosphorylated Rab substrates (Rab1, Rab3, Rab8, Rab10, Rab35 and Rab43) as well as total levels of Rabs, LRRK2 and LRRK2-phosphorylated at the Ser910 and Ser935 biomarker sites. Exploiting this assay, we quantify for the first time the relative levels of each of the pRab proteins in different cells (mouse embryonic fibroblasts, human neutrophils) and mouse tissues (brain, kidney, lung and spleen). We define how these components are impacted by Parkinson’s pathogenic mutations (LRRK2(R1441C) and VPS35(D620N)) and LRRK2 inhibitors. We find that the VPS35(D620N), but not LRRK2(R1441C) mutation, enhances Rab1 phosphorylation in a manner blocked by administration of an LRRK2 inhibitor, providing the first evidence that endogenous Rab1 is a physiological substrate for LRRK2. We exploit this assay to demonstrate that in Parkinson’s patients with VPS35(D620N) mutations, phosphorylation of multiple Rab proteins (Rab1, Rab3, Rab8, Rab10 and Rab43) is elevated. We highlight the benefits of this assay over immunoblotting approaches currently deployed to assess LRRK2 Rab signalling pathway.

Presenter: Raja Nirujogi (Post Doc, University of Dundee)